All In Biotech

NDA 212854 · Zmi Pharma

Zimhi

Naloxone Hydrochloride · Intramuscular, Subcutaneous

Last checked: Nov 20, 2026Latest source record: Oct 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 15, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

933

752 serious, 140 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 4, 2025.

1. INDICATIONS AND USAGE ZIMHI is indicated in adults and pediatric patients for: the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care. ZIMHI is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. ( 1 ) ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) ZIMHI is not a substitute for emergency medical care. ( 1 )

Mechanism: Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 15, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZIMHI · NALOXONE HYDROCHLORIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective97
  • toxicity to various agents90
  • vomiting58
  • fatigue49
  • off label use49
  • overdose48
  • drug withdrawal syndrome46
  • nausea46
  • diarrhoea40
  • pain40
  • febrile neutropenia32
  • fall31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20072
20083
200910
20108
20113
20129
20139
201410
201515
201626
201735
201859
201950
2020128
202185
2022106
202394
2024117
2025103
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zimhi (Naloxone HCl)

2024 spending

$5K

Beneficiaries

27

31 claims

Per beneficiary

$169

$125.00 per unit

View as table
YearSpending
2020$0
2021$0
2022$13,308
2023$10,838
2024$4,563

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,733 on PubMed

Sponsor: Zmi Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.